Company

Ectin Research is managed by a core team of senior professionals from the pharmaceutical industry, clinical physicians and scientists from the academic world in a semi-virtual organization. Where a large network of external complementing competences is consulted when required.

Board of directors

Image for Fredrik Sjövall

Fredrik Sjövall

Chairman of the Board

Fredrik has +15y of experience from management positions in the life science industry. He was previously CEO of Hemcheck, Inhalation Sciences, Lipopeptide and PharmaSurgics. Fredrik is currently the Chairman at the publicly listed companies Ziccum, Lipidor and Monivent. He is also the Chairman of Emollivet, and Axelero.

Image for Carlos de Sousa, MD, MBA

Carlos de Sousa, MD, MBA

Board member

Carlos is a seasoned industry executive with 30 years of experience ranging from leadership positions at international pharmaceutical companies such as Pfizer, Novartis and Nycomed/Takeda, to executive management roles at innovative biotech companies, for which he achieved several rounds of successful capital increases, supported the up-listing to the main market of Nasdaq Stockholm, and enabled the advance of early to mid-stage product development pipelines. Carlos has also amassed extensive experience in business development, licensing agreements and strategic partnerships and brings to Ectin the benefit of a broad and international industry network. He is currently the CEO at Ultimovacs (publ), Oslo. His previous position was President and Chief Executive Officer of Immunicum AB.

Image for Christer Edlund, MD, PhD

Christer Edlund, MD, PhD

Board member & co-founder

Christer is Senior Consultant in Urology, working at Kungsbacka Hospital, in Region Halland. Christer has broad cancer therapy experience from treating urology patients for many years and a substantial clinical network.

Image for Marie-Lois Ivarsson, MD, Associate Professor

Marie-Lois Ivarsson, MD, Associate Professor

Board member & co-founder

Marie-Lois is Associate Professor, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska academy, the University of Gothenburg. She has a significant academic network, extensive knowledge within the field of cancer treatment and has taken part in a number of large clinical trials.

Image for Peter Falk, PhD

Peter Falk, PhD

Board member & co-founder

Peter is scientist at the Sahlgrenska academy, university of Gothenburg. He has wide experience of different experimental models and of methodological techniques for protein detection and a significant network in the scientific community.

Image for Anders Waas

Anders Waas

Board member

Anders is business coach at GU Ventures. He has more than 30 years’ experience of global business development and product development in the pharmaceutical, biotech and medical technology industry e.g. Astra Zeneca, CV Therapeutics and WL Gore & Associates, as CEO of TikoMed and a large number of board positions.

Image for Fredrik Andersson

Fredrik Andersson

Board member

Fredrik Has ownership in the company and a strong background in pharmaceutical investment. Co-founded and sat in the board of another life science company.

Management

Image for Anna Sjöblom-Hallén, PhD, MBA

Anna Sjöblom-Hallén, PhD, MBA

CEO

Anna is an entrepreneur with extensive experience from her previous work as CEO, and as project manager of different start-ups in the Life Science field where she has managed to create profitable businesses. She has a broad network and knowledge of financing companies, conducting international out-licensing and from heading pharmaceutical development.

Image for Michael Owens

Michael Owens

CFO

With a BSBA (Bachelor Business Administration in accounting and auditing) Michael Owens has held executive finance positions in both the US and Sweden. From 2007 – 2012 he was Group Controller of Karolinska Development, playing a key role in successfully taking the company public in 2011. He has extensive executive experience in the medtech research field, guiding companies surely through a complex legislative and fiscal landscape.

Image for Steven Glazer, MD

Steven Glazer, MD

CMO

Steven is an experienced healthcare and biotech professional with extensive knowledge of research and development, medical and regulatory affairs. His background encompasses senior management and hands-on experience from pharmaceutical, biopharmaceutical, biotechnology and diagnostic industries in Europe and the United States. With previous positions such as Medical Director Novo Nordisk, Senior Vice President BioInvent, CMO Hansa Medical and current positions: CMO RhoVac, CMO Idogen, Board Member, Immunicum, and Partner Ventac Partners.

Partnership opportunities

Ectin Research welcomes established companies in the oncology field in the discussion of potential commercial opportunities using the company’s proprietary technology.

For more information about the company and for the discussion of potential commercial opportunities please contact Anna Sjöblom-Hallén, CEO. anna.sjoblom-hallen@ectinresearch.com